Foresee Pharmaceuticals
Biotechnology ResearchTaipei City, Taiwan11-50 Employees
Foresee Pharmaceuticals is a biotechnology company with operations in Taiwan and the United States. It concentrates on two main avenues: a Stabilized Injectable Formulation (SIF) platform that enables long-acting injectable therapies for specialty markets, and a pipeline of preclinical and clinical first-in-class programs targeting rare and severe diseases with high unmet needs. Its portfolio includes CAMCEVI, a prostate cancer therapy with a six-month injectable formulation that has regulatory approvals in the United States, Canada, the European Union, Taiwan, and Israel and has been launched in the United States; a three-month version of CAMCEVI is in NDA submission, and a Phase 3 study for CPP is under way. Additional programs include FP-025 and FP-020, oral MMP-12 inhibitors for inflammatory and fibrotic conditions, and FP-045, an oral ALDH2 activator being studied through the FuschiA Phase 1b/2 trial for Fanconi anemia, with the Phase 2 WINDWARD study in PH-ILD planned to begin in the fourth quarter of 2024. The company is listed on the Taipei Exchange and is headquartered in Taipei, Taiwan; in March 2026, the CHMP issued a positive opinion for Camcevi 21 mg in the EU.
1-888-653-2347 
support@leadiq.com 
